English

PROMETHEUS BIOSCIENCES, INC.

EDGAR

RXDX Quarterly report (10-Q) · filed 2023-05-09

11 filing records in this dataset, filed from 2021-02-19 to 2023-05-09. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

1.11 million USD

2023 Q1 · USD

Exact inputs and evidence

Revenue: 1105000 USD Source

Operating margin

-4,407.6%

2023 Q1 · %

Exact inputs and evidence

Operating Income: -48704000 USD Source
Revenue: 1105000 USD Source

Operating cash flow

-39.5 million USD

2023 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -39544000 USD Source

Free cash flow

-40.1 million USD

2023 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -39544000 USD Source
Capital Expenditure: 530000 USD Source

Cash and cash equivalents: 113 million USD 2023-03-31 Source
Exact value

113345000 USD
Long-term debt including current maturities: 7.4 million USD 2021-06-30 Source
Exact value

7396000 USD
Shares outstanding: 47.7 million shares 2023-03-31 Source
Exact value

47714178 shares

Reported share-count change

22.06% · 8.62 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

39089812 shares · 2022-03-31· Source
47714178 shares · 2023-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

4 million USD

2022-04-01 – 2023-03-31

Exact inputs and evidence

Revenue: 1269000 USD · 2022-04-01 – 2022-06-30 Source
Revenue: 968000 USD · 2022-07-01 – 2022-09-30 Source
Revenue: 6809000 USD · 2022-01-01 – 2022-12-31 Source
Revenue: 6156000 USD · 2022-01-01 – 2022-09-30 Source
Revenue: 1105000 USD · 2023-01-01 – 2023-03-31 Source

Net income

-151 million USD

2022-04-01 – 2023-03-31

Exact inputs and evidence

Net income: -33647000 USD · 2022-04-01 – 2022-06-30 Source
Net income: -37275000 USD · 2022-07-01 – 2022-09-30 Source
Net income: -141752000 USD · 2022-01-01 – 2022-12-31 Source
Net income: -102988000 USD · 2022-01-01 – 2022-09-30 Source
Net income: -40876000 USD · 2023-01-01 – 2023-03-31 Source

Operating cash flow

-133 million USD

2022-04-01 – 2023-03-31

Exact inputs and evidence

Operating cash flow: -58235000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -29388000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -82131000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -58235000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -123254000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -82131000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -39544000 USD · 2023-01-01 – 2023-03-31 Source

Capital expenditure

2.28 million USD

2022-04-01 – 2023-03-31

Exact inputs and evidence

Capital expenditure: 1843000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 955000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 2334000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 1843000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 2703000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 2334000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 530000 USD · 2023-01-01 – 2023-03-31 Source

Free cash flow

-136 million USD

2022-04-01 – 2023-03-31

Exact inputs and evidence

Operating cash flow: -58235000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -29388000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -82131000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -58235000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -123254000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -82131000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -39544000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 1843000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 955000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 2334000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 1843000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 2703000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 2334000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 530000 USD · 2023-01-01 – 2023-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-05-09.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2022-12-31
Operating income: 3 of 11 periods available· newest 2022-12-31
Net income: 3 of 11 periods available· newest 2022-12-31
Operating cash flow: 3 of 11 periods available· newest 2022-12-31
Capital expenditure: 3 of 11 periods available· newest 2022-12-31
Total assets: 3 of 11 periods available· newest 2022-12-31
Total liabilities: 3 of 11 periods available· newest 2022-12-31
Current assets: 3 of 11 periods available· newest 2022-12-31
Current liabilities: 3 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2022-12-31
long term debt: No compatible figures in this window
Shares outstanding: 3 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+117.6%

Prior period

USD 3.13 million

2021-01-01 – 2021-12-31
Current period

USD 6.81 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

6809000 − 3129000 = 3680000 USD

3129000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
6809000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · PROMETHEUS BIOSCIENCES, INC. · 2022-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Year-over-year change in Revenue: 3680000 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 6809000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#1692933 Filing: 000095017023005097 Input fundies:Revenue: 3129000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#1694935 Filing: 000095017023005097
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 51.56 million

Prior period

−USD 90.2 million

2021-01-01 – 2021-12-31
Current period

−USD 141.75 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-141752000 − -90195000 = -51557000 USD

-90195000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-141752000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · PROMETHEUS BIOSCIENCES, INC. · 2022-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Year-over-year change in Net income: -51557000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -141752000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2446775 Filing: 000095017023005097 Input fundies:NetIncome: -90195000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2449006 Filing: 000095017023005097
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 59.75 million

Prior period

−USD 63.51 million

2021-01-01 – 2021-12-31
Current period

−USD 123.25 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-123254000 − -63505000 = -59749000 USD

-63505000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-123254000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · PROMETHEUS BIOSCIENCES, INC. · 2022-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Year-over-year change in Operating cash flow: -59749000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -123254000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2612549 Filing: 000095017023005097 Input fundies:OperatingCashFlow: -63505000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2614873 Filing: 000095017023005097
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+137.9%

Prior period

USD 1.14 million

2021-01-01 – 2021-12-31
Current period

USD 2.7 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

2703000 − 1136000 = 1567000 USD

1136000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
2703000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · PROMETHEUS BIOSCIENCES, INC. · 2022-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Year-over-year change in Capital expenditure: 1567000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 2703000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2624148 Filing: 000095017023005097 Input fundies:CapitalExpenditure: 1136000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2626332 Filing: 000095017023005097
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 6.81 million 100% of revenue
Operating costs Derived USD 152.59 million 2,241% of revenue
Operating income −USD 145.78 million −2,141% of revenue
Tax, interest and other Derived −USD 4.03 million −59% of revenue
Net income −USD 141.75 million −2,082% of revenue

Cash

Operating cash flow −USD 123.25 million −1,810% of revenue
Capital expenditure USD 2.7 million 40% of revenue
Free cash flow Derived −USD 125.96 million −1,850% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 2,460% of revenue.
2021 Operating loss: operating costs were 2,906% of revenue.
2022 Operating loss: operating costs were 2,241% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	1229000	30236000 Derived	-29007000	8131000 Derived	-37138000	-28222000 Derived	Source 2020-01-01 – 2020-12-31: 1229000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -29007000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -37138000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -28018000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 204000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	3129000	90932000 Derived	-87803000	2392000 Derived	-90195000	-64641000 Derived	Source 2021-01-01 – 2021-12-31: 3129000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -87803000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -90195000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -63505000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1136000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	6809000	152587000 Derived	-145778000	-4026000 Derived	-141752000	-125957000 Derived	Source 2022-01-01 – 2022-12-31: 6809000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -145778000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -141752000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -123254000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 2703000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 6.8M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	1229000	Revenue: 1229000 Open source
20212021-12-31	Revenue	3129000	Revenue: 3129000 Open source
20222022-12-31	Revenue	6809000	Revenue: 6809000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

117.6% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 1229000 Open source
20212021-12-31	Year over year	154.6%	Revenue: 3129000 Open source Revenue: 1229000 Open source
20222022-12-31	Year over year	117.6%	Revenue: 6809000 Open source Revenue: 3129000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -2,141% 2022

Net margin -2,081.8% 2022

Free cash flow margin -1,849.9% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-2,360.2%	Operating Income: -29007000 Open source Revenue: 1229000 Open source
20212021-12-31	Operating margin	-2,806.1%	Operating Income: -87803000 Open source Revenue: 3129000 Open source
20222022-12-31	Operating margin	-2,141%	Operating Income: -145778000 Open source Revenue: 6809000 Open source
20202020-12-31	Net margin	-3,021.8%	Net Income: -37138000 Open source Revenue: 1229000 Open source
20212021-12-31	Net margin	-2,882.6%	Net Income: -90195000 Open source Revenue: 3129000 Open source
20222022-12-31	Net margin	-2,081.8%	Net Income: -141752000 Open source Revenue: 6809000 Open source
20202020-12-31	Free cash flow margin	-2,296.3%	Revenue: 1229000 Open source Operating Cash Flow: -28018000 Open source Capital Expenditure: 204000 Open source
20212021-12-31	Free cash flow margin	-2,065.9%	Revenue: 3129000 Open source Operating Cash Flow: -63505000 Open source Capital Expenditure: 1136000 Open source
20222022-12-31	Free cash flow margin	-1,849.9%	Revenue: 6809000 Open source Operating Cash Flow: -123254000 Open source Capital Expenditure: 2703000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -123.3M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-28018000	Operating Cash Flow: -28018000 Open source
20212021-12-31	Operating cash flow	-63505000	Operating Cash Flow: -63505000 Open source
20222022-12-31	Operating cash flow	-123254000	Operating Cash Flow: -123254000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -126M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-28222000	Operating Cash Flow: -28018000 Open source Capital Expenditure: 204000 Open source
20212021-12-31	Free cash flow	-64641000	Operating Cash Flow: -63505000 Open source Capital Expenditure: 1136000 Open source
20222022-12-31	Free cash flow	-125957000	Operating Cash Flow: -123254000 Open source Capital Expenditure: 2703000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

8.7% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	52.2%	Total Liabilities: 31151000 Open source Total Assets: 59633000 Open source
20212021-12-31	Liabilities / assets	12.2%	Total Liabilities: 32646000 Open source Total Assets: 267801000 Open source
20222022-12-31	Liabilities / assets	8.7%	Total Liabilities: 64805000 Open source Total Assets: 740773000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

31.04× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	3.77×	Current Assets: 57456000 Open source Current Liabilities: 15255000 Open source
20212021-12-31	Current assets / current liabilities	16.14×	Current Assets: 265383000 Open source Current Liabilities: 16442000 Open source
20222022-12-31	Current assets / current liabilities	31.04×	Current Assets: 708151000 Open source Current Liabilities: 22817000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 37.14 million Exact value Exact value: -37138000 USD 2020-01-01 – 2020-12-31: -37138000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PROMETHEUS BIOSCIENCES, INC. · 2020-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Net Income: -37138000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -37138000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2451236 Filing: 000095017023005097 The citation records this snapshot. The page link may show a newer release later.	−USD 28.02 million Exact value Exact value: -28018000 USD 2020-01-01 – 2020-12-31: -28018000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PROMETHEUS BIOSCIENCES, INC. · 2020-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Operating Cash Flow: -28018000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28018000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2617196 Filing: 000095017023005097 The citation records this snapshot. The page link may show a newer release later.	USD 204,000 Exact value Exact value: 204000 USD 2020-01-01 – 2020-12-31: 204000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PROMETHEUS BIOSCIENCES, INC. · 2020-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Capital Expenditure: 204000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 204000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2628516 Filing: 000095017023005097 The citation records this snapshot. The page link may show a newer release later.	−USD 28.22 million Calculation and evidence -28018000 − 204000 USD Exact free cash flow: -28222000 USD 2020-01-01 – 2020-12-31: -28018000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 204000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PROMETHEUS BIOSCIENCES, INC. · 2020-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Free cash flow: -28222000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28018000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2617196 Filing: 000095017023005097 Input fundies:CapitalExpenditure: 204000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2628516 Filing: 000095017023005097 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 90.2 million Exact value Exact value: -90195000 USD 2021-01-01 – 2021-12-31: -90195000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PROMETHEUS BIOSCIENCES, INC. · 2021-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Net Income: -90195000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -90195000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2449006 Filing: 000095017023005097 The citation records this snapshot. The page link may show a newer release later.	−USD 63.51 million Exact value Exact value: -63505000 USD 2021-01-01 – 2021-12-31: -63505000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PROMETHEUS BIOSCIENCES, INC. · 2021-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Operating Cash Flow: -63505000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -63505000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2614873 Filing: 000095017023005097 The citation records this snapshot. The page link may show a newer release later.	USD 1.14 million Exact value Exact value: 1136000 USD 2021-01-01 – 2021-12-31: 1136000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PROMETHEUS BIOSCIENCES, INC. · 2021-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Capital Expenditure: 1136000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1136000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2626332 Filing: 000095017023005097 The citation records this snapshot. The page link may show a newer release later.	−USD 64.64 million Calculation and evidence -63505000 − 1136000 USD Exact free cash flow: -64641000 USD 2021-01-01 – 2021-12-31: -63505000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1136000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PROMETHEUS BIOSCIENCES, INC. · 2021-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Free cash flow: -64641000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -63505000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2614873 Filing: 000095017023005097 Input fundies:CapitalExpenditure: 1136000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2626332 Filing: 000095017023005097 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 141.75 million Exact value Exact value: -141752000 USD 2022-01-01 – 2022-12-31: -141752000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PROMETHEUS BIOSCIENCES, INC. · 2022-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Net Income: -141752000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -141752000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2446775 Filing: 000095017023005097 The citation records this snapshot. The page link may show a newer release later.	−USD 123.25 million Exact value Exact value: -123254000 USD 2022-01-01 – 2022-12-31: -123254000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PROMETHEUS BIOSCIENCES, INC. · 2022-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Operating Cash Flow: -123254000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -123254000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2612549 Filing: 000095017023005097 The citation records this snapshot. The page link may show a newer release later.	USD 2.7 million Exact value Exact value: 2703000 USD 2022-01-01 – 2022-12-31: 2703000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PROMETHEUS BIOSCIENCES, INC. · 2022-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Capital Expenditure: 2703000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2703000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2624148 Filing: 000095017023005097 The citation records this snapshot. The page link may show a newer release later.	−USD 125.96 million Calculation and evidence -123254000 − 2703000 USD Exact free cash flow: -125957000 USD 2022-01-01 – 2022-12-31: -123254000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 2703000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PROMETHEUS BIOSCIENCES, INC. · 2022-12-31 PROMETHEUS BIOSCIENCES, INC. (edgar:1718852) Free cash flow: -125957000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:12:24Z Snapshot: b896c0bd3e21ada93429b14405d4b6055de939464e2b152436227b8617e5233d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1718852?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -123254000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2612549 Filing: 000095017023005097 Input fundies:CapitalExpenditure: 2703000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1718852/000095017023005097/rxdx-20221231.htm#2624148 Filing: 000095017023005097 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

11 filings · 737 latest values · 737 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001718852, 1718852, RXDX, edgar:1718852

Also known as PROMETHEUS BIOSCIENCES, INC., Precision IBD, Inc., Prometheus Biosciences, Inc.

PROMETHEUS BIOSCIENCES, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation